Clinical Utility of Fructosamine and Glycated Albumin
Introduction
Diabetes mellitus, a global epidemic, is increasing at an alarming rate and is associated with both increased morbidity and mortality. Globally, 589 million adults between the ages of 20 and 79 are living with diabetes mellitus, which is approximately 1 in every 9 people. This number is projected to rise to 853 million by 2050.[1] As of 2024, the United States has 38.5 million adults in this age group living with diabetes mellitus, ranking third worldwide in terms of diabetes prevalence. The United States also accounts for the highest total diabetes mellitus–related health expenditure globally.[2] Currently, only plasma glucose and glycated hemoglobin (HbA1c) are universally accepted as reliable measures of diabetes control. In certain conditions, the HbA1c measurement is not reliable. An example is in patients with red blood cell (RBC) disorders and renal disease. Fructosamine, which is a measure of non-enzymatic glycation of circulating proteins, including albumin, globulins, and lipoproteins, has evolved to be a reasonable alternative to HbA1c measurement in situations where HbA1c is not reliable. Because albumin is the most abundant of the serum proteins, fructosamine is predominantly a measure of glycated albumin, which represents the percentage of albumin that is glycated. Fructosamine and glycated albumin have a potential role in the diagnosis, monitoring, and management of diabetes mellitus.[3][4][5]
Pathophysiology
Register For Free And Read The Full Article
Search engine and full access to all medical articles
10 free questions in your specialty
Free CME/CE Activities
Free daily question in your email
Save favorite articles to your dashboard
Emails offering discounts
Learn more about a Subscription to StatPearls Point-of-Care
Pathophysiology
HbA1c is a product of nonenzymatic glycation of hemoglobin. RBCs have a lifespan of approximately 90 to 120 days; hence, HbA1c indicates the mean blood glucose concentration over the lifespan of the RBC. HbA1c is influenced by conditions affecting RBC survival. Conditions causing low RBC turnover, such as untreated iron, vitamin B12, or folic acid deficiency anemias, result in falsely high HbA1c values. On the other hand, conditions causing high RBC turnover, such as hemolytic anemia, can result in falsely low HbA1c values. This phenomenon can occur in patients treated for iron, vitamin B12, or folate deficiencies, as well as in those treated with erythropoietin, such as individuals with chronic kidney disease.
Fructosamine (1-amino-1-deoxy fructose) is a stable ketoamine formed by the reaction between glucose and the amino group of protein, predominantly albumin, but also including globulins and lipoproteins. The attachment of the aldehyde group of the carbohydrate with the N-terminal amino acid of the protein forms the reversible Schiff base product, the aldimine intermediate. The Schiff base product may be converted back to glucose and protein, or undergo the Amadori rearrangement to form stable fructosamine. This process is known as nonenzymatic glycation and is also referred to as the Maillard reaction. The Maillard reaction causes the browning phenomenon that occurs in milk and other food products when heated. Glycated albumin refers to the formation of ketoamine, specifically involving the major circulating protein albumin (3.5-5 g/dL). Glycated albumin is an example of a fructosamine. Because albumin is the most abundant of the serum proteins, fructosamine is predominantly a measure of glycated albumin. The formation of fructosamine and glycated albumin represents post-translational protein modifications.
Non-immunoglobulin serum proteins have a much lower half-life, approximately 14 to 21 days.[6] The measurement of fructosamine or glycated albumin provides information on glucose control within the previous 2 to 3 weeks. Another important difference with HbA1c is the rate of nonenzymatic glycation of albumin, which is approximately 9- to 10-fold higher than that of HbA1c.[7][8]
Specimen Requirements and Procedure
Serum or plasma is the sample type used for the measurement of fructosamine and glycated albumin. Fasting specimens are not required.
Testing Procedures
Fructosamine
A colorimetric assay is the most commonly used method for measuring serum fructosamine, which uses the reduction of the dye nitroblue tetrazolium to formazan. The rate of formazan formation is directly proportional to the fructosamine concentration and is measured using the spectrophotometric technique.[9] These assays are widely available, can be automated, and are relatively inexpensive. The reference range for fructosamine in non-diabetic individuals is generally 200 to 285 µmol/L. However, unlike HbA1c, there is a serious lack of standardization across the different fructosamine assays.
Glycated Albumin
Several assay methodologies are available for analyzing glycated albumin, including:
- Enzymatic assay
- High-performance liquid chromatography and affinity chromatography
- Immunoassay, including quantification by radioimmunoassay
- Enzyme-linked immunosorbent assay
- Enzyme-linked boronate immunoassay
- Colorimetry
- Electrochemical assay
The enzymatic assay (Lucica GA-L kit, Asahi Kasei Pharma, Tokyo, Japan) is easier to use, highly accurate, and automated.[10] First, there is the elimination of endogenous glycated amino acids and peroxide by a ketoamine oxidase, followed by a peroxidase reaction.[11] An albumin-specific proteinase hydrolyzes the glycated albumin. The products of this reaction are oxidized by ketoamine oxidase to hydrogen peroxide, which is then measured quantitatively using a colorimetric method. The albumin concentration is also measured concurrently. The final result is expressed as the ratio of glycated to total albumin.[12]
The normal value is around 14%, and it increases to greater than 17% in patients with diabetes mellitus. Values in diabetes mellitus can go as high as 2 to 5 times the upper limit of normal.
Interfering Factors
Fructosamine assays are influenced by changes in temperature and by the increased levels of reducing substances in serum, such as vitamin C and bilirubin. Fructosamine and glycated albumin lack standardized assays, and their measurements are influenced by any condition that alters serum albumin concentrations. However, this limitation is minimized for glycated albumin, as results are expressed as a percentage of total albumin. Fructosamine is unreliable when serum albumin is less than 3.0 g/dL. This limitation applies to conditions associated with reduced albumin synthesis, such as liver cirrhosis, as well as those involving albumin or protein loss, including nephrotic syndrome and protein-losing enteropathies. Fructosamine levels may also be influenced by conditions associated with elevated total protein levels, such as multiple myeloma (due to increased immunoglobulins) and polyclonal gammopathies.[13][14]
Results, Reporting, and Critical Findings
The reference range for fructosamine in non-diabetic individuals is typically 200 to 285 μmol/L. Although glycated albumin assays also suffer from standardization issues, the newer assay developed by Asahi Kasei has shown significant improvement. According to this assay, healthy individuals have values around 14% and those with diabetes mellitus have greater than 17%. In cases of diabetes mellitus, levels can reach as high as 2 to 5 times the upper limit of normal.
Clinical Significance
The clinical utility of fructosamine and glycated albumin includes monitoring of diabetes mellitus, diagnosis of pre-diabetes mellitus, and prediction of both the microvascular and macrovascular complications. An added advantage is that their measurement does not require a fasting sample.
Monitoring Glucose Control in Diabetes Mellitus
Fructosamine and glycated albumin can be used as short-term markers of glucose control. Both correlate significantly with HbA1c levels. Although HbA1c reflects glucose control over the preceding 8 to 12 weeks, fructosamine reflects the average glycemia over the preceding 2 to 3 weeks. This difference is a result of the inherent shorter half-life of albumin compared to hemoglobin in the erythrocyte.
Fructosamine has largely been used as an alternative to HbA1c in certain conditions that limit the reliability of HbA1c, such as hemoglobin variants and alterations in erythrocyte lifespan. Unlike HbA1c, fructosamine and glycated albumin are unaffected by hemoglobin levels or RBC characteristics, making them reliable markers in conditions such as hemoglobinopathies, sickle cell anemia, and anemias due to iron, vitamin B12, or folate deficiency. Additionally, fructosamine has clinical utility in conditions where information regarding short-term glucose control is important in the management of the patient, such as in pregnancy or recent medication adjustment. Fructosamine and glycated albumin can also be useful in monitoring individuals with diabetes mellitus with fluctuating or poorly controlled diabetes.
Diagnosis of Diabetes Mellitus
Recent studies have investigated the use of the alternate glycaemic markers, such as fructosamine and glycated albumin, for diagnosing diabetes mellitus. During the diagnosis of diabetes, serum glycated albumin measurements have been reported to aid in determining the need for an oral glucose tolerance test. Glycated albumin shows a negative correlation with body mass index, which may lead to an underestimation of glycemic status in individuals with obesity. Currently, no guidelines support the use of glycated albumin or fructosamine for diagnosing diabetes mellitus or pre-diabetes mellitus.[12]
Diabetes Mellitus–Related Outcomes
Previously, limited evidence was available regarding the relationship of fructosamine and glycated albumin with diabetes mellitus complications and long-term outcomes. Recent studies, for example, the Atherosclerosis Risk in Communities Study (ARIC), have demonstrated that fructosamine and glycated albumin were strongly associated with retinopathy as well as significantly associated with the risk of incident chronic kidney disease and incident diabetes mellitus. Besides, both fructosamine and glycated albumin, even after adjustment for HbA1c, are significant prognosticators of cardiovascular outcomes and mortality.[15]
Quality Control and Lab Safety
Quality assurance is crucial for ensuring the accuracy and reliability of fructosamine testing, which primarily involves 2 key components—internal quality control (IQC) and proficiency testing. IQC is conducted using control materials provided either by the assay manufacturer or third-party suppliers. These materials are used to verify system performance after the analyzer has been calibrated or standardized for fructosamine measurement.[16]
Controls are run at specified intervals, with the frequency determined through a risk assessment of the testing process. The results are recorded on Levey–Jennings charts and assessed using statistical criteria such as the Westgard rules. Any rule violations trigger a root cause analysis to identify whether the error is random or systematic. Appropriate corrective measures are then implemented, and the controls are repeated until the results fall within acceptable limits. Only after this can patient testing resume, following the supervising pathologist's approval.[17]
Patient samples must not be tested if control results are out of range, as this could produce inaccurate results. In compliance with ISO 15189 standards, all patient samples processed after the last acceptable IQC run must be reviewed and retested once the problem is resolved. Laboratories must select IQC materials that are stable, closely mimic patient sample matrices and behavior, present clinically relevant challenges near decision thresholds, and preferably span the assay's measurement range.[18][19]
Equally important is participation in proficiency testing or external quality assessment programs. These programs allow laboratories to benchmark their performance against peers, detect possible biases, and enhance assay reliability. Laboratories are required to have well-defined policies for enrollment, participation, and management of unsatisfactory results.[20][21]
Additionally, laboratory safety is vital in clinical testing. Staff must consistently use proper personal protective equipment, maintain good hand hygiene, and be trained in safety procedures, including the use of eyewash stations, biological and chemical spill kits, and precautions against bloodborne pathogens. A biosafety manual should be accessible to all personnel, with regular training and competency evaluations to ensure compliance with safe laboratory practices.[22][23]
Enhancing Healthcare Team Outcomes
Healthcare professionals, including nurse practitioners, should be familiar with the diagnosis of diabetes mellitus. Fructosamine and glycated albumin can be used as alternative markers in patients where the HbA1c assay is unreliable. Additionally, they can identify poor glucose control more rapidly than HbA1c, ie, short-term hyperglycemia. A major promise of the tests is their ability to predict those pre-diabetic patients who progress to clinical diabetes, as this could lead to major lifestyle and pharmacological interventions to prevent the onset of diabetes and its complications. Finally, they may also have a role in the management of diabetes mellitus during pregnancy, as pregnant patients need frequent glucose monitoring. Unlike HbA1c, which reflects glycemia over 8 to 12 weeks, fructosamine and glycated albumin provide insight into glucose levels over a shorter period of 2 to 3 weeks.[24]
Glycated albumin has been reported to be a better marker than HbA1c for the assessment of glucose control in people with diabetes mellitus who have chronic kidney disease and those on hemodialysis and peritoneal dialysis.[25][26]
References
Hossain MJ, Al-Mamun M, Islam MR. Diabetes mellitus, the fastest growing global public health concern: Early detection should be focused. Health science reports. 2024 Mar:7(3):e2004. doi: 10.1002/hsr2.2004. Epub 2024 Mar 22 [PubMed PMID: 38524769]
Fang M, Wang D, Selvin E. Prevalence of Type 1 Diabetes Among US Children and Adults by Age, Sex, Race, and Ethnicity. JAMA. 2024 Apr 23:331(16):1411-1413. doi: 10.1001/jama.2024.2103. Epub [PubMed PMID: 38573653]
Neelofar K, Ahmad J. A comparative analysis of fructosamine with other risk factors for kidney dysfunction in diabetic patients with or without chronic kidney disease. Diabetes & metabolic syndrome. 2019 Jan-Feb:13(1):240-244. doi: 10.1016/j.dsx.2018.08.007. Epub 2018 Aug 10 [PubMed PMID: 30641705]
Level 2 (mid-level) evidenceGarrahy A, Mijares Zamuner MB, Byrne MM. An evolving spectrum of diabetes in a woman with GCK-MODY. Endocrinology, diabetes & metabolism case reports. 2019 Jan 3:2019():. pii: EDM180145. doi: 10.1530/EDM-18-0145. Epub 2019 Jan 3 [PubMed PMID: 30608898]
Pedrosa W, Sander Diniz MFH, Barreto SM, Vidigal PG. Establishing a blood fructosamine reference range for the Brazilian population based on data from ELSA - Brasil. Practical laboratory medicine. 2019 Jan:13():e00111. doi: 10.1016/j.plabm.2018.e00111. Epub 2018 Dec 5 [PubMed PMID: 30581949]
Roohk HV, Zaidi AR. A review of glycated albumin as an intermediate glycation index for controlling diabetes. Journal of diabetes science and technology. 2008 Nov:2(6):1114-21 [PubMed PMID: 19885300]
Muñoz-Prieto A, Escribano D, Cerón JJ, Martínez-Subiela S, Tvarijonaviciute A. Glucose, fructosamine, and insulin measurements in saliva of dogs: variations after an experimental glucose administration. Domestic animal endocrinology. 2019 Jan:66():64-71. doi: 10.1016/j.domaniend.2018.10.002. Epub 2018 Oct 25 [PubMed PMID: 30472034]
Level 3 (low-level) evidenceGingras V, Rifas-Shiman SL, Switkowski KM, Oken E, Hivert MF. Mid-Pregnancy Fructosamine Measurement-Predictive Value for Gestational Diabetes and Association with Postpartum Glycemic Indices. Nutrients. 2018 Dec 18:10(12):. doi: 10.3390/nu10122003. Epub 2018 Dec 18 [PubMed PMID: 30567328]
Rivera-Velez SM, Hwang J, Navas J, Villarino NF. Identification of differences in the formation of plasma glycated proteins between dogs and humans under diabetes-like glucose concentration conditions. International journal of biological macromolecules. 2019 Feb 15:123():1197-1203. doi: 10.1016/j.ijbiomac.2018.11.188. Epub 2018 Nov 19 [PubMed PMID: 30465839]
Kouzuma T, Usami T, Yamakoshi M, Takahashi M, Imamura S. An enzymatic method for the measurement of glycated albumin in biological samples. Clinica chimica acta; international journal of clinical chemistry. 2002 Oct:324(1-2):61-71 [PubMed PMID: 12204426]
Kouzuma T, Uemastu Y, Usami T, Imamura S. Study of glycated amino acid elimination reaction for an improved enzymatic glycated albumin measurement method. Clinica chimica acta; international journal of clinical chemistry. 2004 Aug 16:346(2):135-43 [PubMed PMID: 15256314]
Kohzuma T, Koga M. Lucica GA-L glycated albumin assay kit: a new diagnostic test for diabetes mellitus. Molecular diagnosis & therapy. 2010 Feb 1:14(1):49-51 [PubMed PMID: 20121290]
Danese E, Montagnana M, Nouvenne A, Lippi G. Advantages and pitfalls of fructosamine and glycated albumin in the diagnosis and treatment of diabetes. Journal of diabetes science and technology. 2015 Mar:9(2):169-76. doi: 10.1177/1932296814567227. Epub 2015 Jan 14 [PubMed PMID: 25591856]
Nansseu JR, Fokom-Domgue J, Noubiap JJ, Balti EV, Sobngwi E, Kengne AP. Fructosamine measurement for diabetes mellitus diagnosis and monitoring: a systematic review and meta-analysis protocol. BMJ open. 2015 May 15:5(5):e007689. doi: 10.1136/bmjopen-2015-007689. Epub 2015 May 15 [PubMed PMID: 25979870]
Level 1 (high-level) evidenceSelvin E, Rawlings AM, Grams M, Klein R, Sharrett AR, Steffes M, Coresh J. Fructosamine and glycated albumin for risk stratification and prediction of incident diabetes and microvascular complications: a prospective cohort analysis of the Atherosclerosis Risk in Communities (ARIC) study. The lancet. Diabetes & endocrinology. 2014 Apr:2(4):279-288. doi: 10.1016/S2213-8587(13)70199-2. Epub 2014 Jan 15 [PubMed PMID: 24703046]
Level 2 (mid-level) evidenceSkitek M, Martinello F, Jerin A. How to Really Understand and Improve the System of Internal Quality Control and External Quality Assessment in the Accreditation Process of the Medical Laboratory? EJIFCC. 2022 Apr:33(1):23-27 [PubMed PMID: 35645692]
Level 2 (mid-level) evidenceGruber L, Hausch A, Mueller T. Internal Quality Controls in the Medical Laboratory: A Narrative Review of the Basic Principles of an Appropriate Quality Control Plan. Diagnostics (Basel, Switzerland). 2024 Oct 5:14(19):. doi: 10.3390/diagnostics14192223. Epub 2024 Oct 5 [PubMed PMID: 39410627]
Level 2 (mid-level) evidenceLinko S, Boursier G, Bernabeu-Andreu FA, Dzneladze N, Vanstapel F, Brguljan PM, Tosheska-Trajkovska K, Mehay H, Panteghini M, Brugnoni D, Milinkovic N, Lohmander M, Šprongl L, Çubukçu HC, Thelen M. EN ISO 15189 revision: EFLM Committee Accreditation and ISO/CEN standards (C: A/ISO) analysis and general remarks on the changes. Clinical chemistry and laboratory medicine. 2025 May 26:63(6):1084-1098. doi: 10.1515/cclm-2024-1451. Epub 2025 Jan 6 [PubMed PMID: 39752732]
Giannoli JM, Vassault A, Carobene A, Liaudet AP, Blasutig IM, Dabla PK, Lin J, Thomas A, Tesser Poloni JA, Meng QH, Amann EP, International Federation of Clinical Chemistry, Laboratory Medicine Task Force on Global Lab Quality TF-GLQ. Ensuring internal quality control practices in medical Laboratories: IFCC recommendations for practical applications based on ISO 15189:2022. Clinica chimica acta; international journal of clinical chemistry. 2025 Apr 15:571():120240. doi: 10.1016/j.cca.2025.120240. Epub 2025 Mar 8 [PubMed PMID: 40064457]
Level 2 (mid-level) evidenceBuchta C, De la Salle B, Marrington R, Aburto Almonacid A, Albarède S, Badrick T, Bullock D, Cobbaert CM, Coucke W, Delatour V, Faria AP, Geilenkeuser WJ, Griesmacher A, Huggett JF, Ianovska V, Kammel M, Kessler A, Körmöczi GF, Meijer P, Miranda A, Patel D, Pezzati P, Sandberg S, Schennach H, Schweiger CR, Schwenoha K, Spannagl M, Sung H, Thelen M, Weykamp C, Zeichhardt H, Restelli V, Perrone LA. Behind the scenes of EQA – characteristics, capabilities, benefits and assets of external quality assessment (EQA): Part V – Benefits for stakeholders other than participants. Clinical chemistry and laboratory medicine. 2025 Apr 28:63(5):898-915. doi: 10.1515/cclm-2024-1293. Epub 2025 Jan 6 [PubMed PMID: 39753240]
Level 2 (mid-level) evidenceBlasutig IM, Wheeler SE, Bais R, Dabla PK, Lin J, Perret-Liaudet A, Thomas A, Cendejas KA, Giannoli JM, Vassault A, Amann E, Meng QH. External quality assessment practices in medical laboratories: an IFCC global survey of member societies. Clinical chemistry and laboratory medicine. 2023 Jul 26:61(8):1404-1410. doi: 10.1515/cclm-2023-0057. Epub 2023 Feb 13 [PubMed PMID: 36779362]
Level 2 (mid-level) evidenceKening MZ, Groen K. Personal Protective Equipment. StatPearls. 2025 Jan:(): [PubMed PMID: 36943957]
Abu-Siniyeh A, Al-Shehri SS. Safety in Medical Laboratories: Perception and Practice of University Students and Laboratory Workers. Applied biosafety : journal of the American Biological Safety Association. 2021 Sep:26(Suppl 1):S34-S42. doi: 10.1089/apb.20.0050. Epub 2021 Sep 13 [PubMed PMID: 36032652]
Roberts AB, Baker JR. Serum fructosamine: a screening test for diabetes in pregnancy. American journal of obstetrics and gynecology. 1986 May:154(5):1027-30 [PubMed PMID: 3706426]
Zheng CM, Ma WY, Wu CC, Lu KC. Glycated albumin in diabetic patients with chronic kidney disease. Clinica chimica acta; international journal of clinical chemistry. 2012 Oct 9:413(19-20):1555-61. doi: 10.1016/j.cca.2012.04.025. Epub 2012 May 10 [PubMed PMID: 22579765]
Freedman BI, Shenoy RN, Planer JA, Clay KD, Shihabi ZK, Burkart JM, Cardona CY, Andries L, Peacock TP, Sabio H, Byers JR, Russell GB, Bleyer AJ. Comparison of glycated albumin and hemoglobin A1c concentrations in diabetic subjects on peritoneal and hemodialysis. Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis. 2010 Jan-Feb:30(1):72-9. doi: 10.3747/pdi.2008.00243. Epub [PubMed PMID: 20056983]